Drug Profile


Alternative Names: Guanabenz - The Myelin Repair Foundation/National Institute of Health; MRF 008

Latest Information Update: 15 May 2015

Price : $50

At a glance

  • Originator Myelin Repair Foundation; National Institute of Neurological Disorders and Stroke
  • Class Antihypertensives; Guanidines
  • Mechanism of Action Immunostimulants; Myelin protein stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 30 Apr 2015 Myelin Repair Foundation plans a phase II trial for Multiple sclerosis in USA
  • 01 Apr 2015 Phase I clinical trial in Multiple sclerosis (Relapsing, remitting) in USA (PO) (NCT02423083)
  • 01 Apr 2015 Preclinical trials in Multiple sclerosis in USA (PO) before April 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top